Loading...
•
Jun 30, 2024
BioCryst Q2 2024 Earnings Report
BioCryst's Q2 2024 earnings were reported, featuring a 34% year-over-year growth in ORLADEYO net revenue, reaching $108.3 million, and increased full-year ORLADEYO revenue guidance to $420-$435 million.
Key Takeaways
BioCryst announced a successful second quarter in 2024, marked by a 34% increase in ORLADEYO net revenue to $108.3 million and a revised full-year revenue guidance of $420-$435 million. The company reported a GAAP operating profit of $8.8 million and a non-GAAP operating profit of $21.9 million. They are also advancing their pipeline programs and moving closer to profitability.
ORLADEYO net revenue grew 34% year-over-year to $108.3 million.
Full-year 2024 ORLADEYO revenue guidance increased to $420-$435 million.
The company generated a GAAP operating profit of $8.8 million in the second quarter.
Non-GAAP operating profit was $21.9 million for the second quarter.
Revenue by Segment
Forward Guidance
BioCryst has raised its outlook for full year 2024 global net ORLADEYO revenue to be between $420 million and $435 million. The company expects full year 2024 operating expenses to be between $365 million and $375 million. They are confident that they will achieve a full-year operating profit in 2024 (not including non-cash stock compensation), be approaching quarterly positive EPS and positive cash flow in the second half of 2025 (not including non-cash stock compensation) and be profitable on an EPS basis, with positive cash flow, for full year 2026.
Positive Outlook
- Full year 2024 global net ORLADEYO revenue is expected to be between $420 million and $435 million.
- Company anticipates achieving a full-year operating profit in 2024 (not including non-cash stock compensation).
- Company is approaching quarterly positive EPS and positive cash flow in the second half of 2025 (not including non-cash stock compensation).
- Company expects to be profitable on an EPS basis, with positive cash flow, for full year 2026.
- Company does not intend to draw the additional $150 million of debt available from Pharmakon.
Challenges Ahead
- Full year 2024 operating expenses are expected to be between $365 million and $375 million.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...